New York, NYNCT05019885Now EnrollingIRB Ready

Drug Resistant Epilepsy Clinical Trial in New York, NY

Access cutting-edge drug resistant epilepsy treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Madeline Fields

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access drug resistant epilepsy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related drug resistant epilepsy treatment provided free

Apply for This New York Location

Check if you qualify for this drug resistant epilepsy clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Drug Resistant Epilepsy Study in New York

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

Sponsor: Madeline Fields

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form
Adults (18 years or older)
Cognitively impaired adults are not excluded (i.e. will be included in the study)
Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs)
EEG consistent with focal or generalized epilepsy
Patients must have \>4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month.
Patients can be on \>/= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation
Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study.

Exclusion Criteria

Patients \<18 years of age
Pregnant women
Women that are breast feeding
Patients who had \>21 days of seizure freedom in the last year.
Patients with a history of status epilepticus within 3 months of screening
Patients with a history of alcoholism of drug misuse within the last 2 years
Unstable medical illness
Serious or imminent suicidal or homicidal risk
Patients with cardiovascular disease
Patients with schizophrenia
Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage
Patients that are immobile i.e. wheel chair bound, bed ridden individuals
Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05019885) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Drug Resistant Epilepsy Treatment Options in New York, NY

If you're searching for drug resistant epilepsy treatment options in New York, NY, this clinical trial (NCT05019885) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced drug resistant epilepsy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all drug resistant epilepsy clinical trials near you to find additional studies recruiting in your area.

More Epilepsy Trials in New York, NY

See all epilepsy clinical trials recruiting in New York — not just this study.

Browse Epilepsy Trials in New York →

Browse More Trials by Condition

Epilepsy TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY